# C2i Genomics

Source: https://onco.cc/companies/c2i-genomics/  
OnCo record `c2i-genomics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

C2i Genomics built a blood test that reads the whole genome of tumour DNA fragments to detect leftover cancer after treatment; Veracyte bought the company in 2024 and now sells the approach as TrueMRD.

## Summary

C2i Genomics, founded in New York with research roots at the New York Genome Center and the Weizmann Institute, developed a whole-genome approach to minimal residual disease (MRD) detection. Rather than tracking a small targeted panel, it sequences the tumour genome to define thousands of somatic variants and applies AI pattern recognition to low-pass whole-genome sequencing of plasma cell-free DNA, giving sensitive detection from a single blood tube. Veracyte announced a definitive agreement to acquire C2i on 8 January 2024 for $70 million in Veracyte shares at closing plus up to $25 million in performance milestones, extending its diagnostics platform into MRD monitoring. The technology now underpins Veracyte's TrueMRD platform, whose first test, for muscle-invasive bladder cancer, is available to order in the United States, with more cancers planned.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: New York, NY
- Type: diagnostics
- Website: https://www.veracyte.com/innovation/truemrd-platform/

## Notes

- c2i-genomics.com redirects to Veracyte. Pre-acquisition venture rounds not sourced. Completion date of the acquisition not separately verified; the 8-K covers the definitive agreement.

## Sources

- Official website: https://www.veracyte.com/innovation/truemrd-platform/
- Veracyte 8-K exhibit announcing C2i acquisition (Jan 2024): https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036dex991.htm

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Casdin Capital](https://onco.cc/companies/casdin-capital/), [Veracyte (Decipher)](https://onco.cc/companies/veracyte/)

---
JSON: https://onco.cc/api/v1/entities/c2i-genomics.json